Ascentage Pharma CMO reports insider holdings
ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Medical Officer Yifan Zhai filed an initial ownership report listing existing holdings, rather than new trades.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ASCENTAGE PHARMA GROUP INTERNATIONAL Chief Medical Officer Yifan Zhai filed an initial ownership report listing existing holdings, rather than new trades. The filing shows options and restricted share units over ordinary shares, vesting in four equal parts on each of 11/26/2026, 2027, 2028 and 2029, plus direct and indirect ordinary share positions held through a trust, spouse and HealthQuest Pharma Limited.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Restricted share units | -- | -- | -- |
| Holding | Restricted share units | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
Footnotes (6)
- F1. Shares held by Dajun Yang Dynasty Trust. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F2. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F3. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
- F4. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.
- F5. Securities held by ordinary shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F6. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Ascentage Pharma (AAPG) Chief Medical Officer Yifan Zhai report in this Form 3?
How many Ascentage Pharma (AAPG) options does Yifan Zhai hold and when do they vest?
When do Yifan Zhai’s Ascentage Pharma (AAPG) options expire and in what currency is the exercise price?
Does this Ascentage Pharma (AAPG) Form 3 show any insider buying or selling by Yifan Zhai?
AI-generated analysis. How Rhea-AI works. Not financial advice.
